Ajinomoto Co., Inc.

    Ajinomoto Co., Inc.

    OOTC:AJINY
    29.28
    USD
    -0.02
    (-0.07%)
    69.81P/E
    Ajinomoto Co., Inc.
    OTC:AJINY
    (OTC Markets)

    Recent

    price

    29.28

    P/E

    ratio

    69.81

    div

    yld

    - -

    ROIC.AI

    2011
    2012
    2013
    2014
    2015
    2016
    2017
    2018
    2019
    2020
    2021
    2022
    2023
    2024
    2025
    2026
    TTM
    JPY
    865.32
    878.54
    756.92
    774.77
    850.22
    977.3
    954.21
    980.44
    1,005.86
    1,003.42
    976.99
    1,058.1
    1,271.29
    691.5
    759.81
    - -
    729.55
    Revenue per Share
    21.78
    30.64
    37.17
    34.33
    39.27
    60.62
    46.4
    52.88
    26.81
    17.18
    54.18
    69.71
    87.99
    41.86
    34.88
    - -
    39.49
    Basic EPS, GAAP
    78.26
    65.78
    64.13
    46.93
    89.01
    61.95
    68.88
    105.03
    102.39
    97.16
    142.7
    127.68
    105.68
    77.76
    100.73
    - -
    80.53
    Free Cash Flow per Basic Share
    8
    8.07
    8.15
    10.13
    10.01
    13.59
    15.08
    15.01
    16.66
    16.01
    15.98
    25.11
    29.59
    18.45
    19.43
    - -
    18.68
    Dividend per Share
    353.99
    384.92
    432.16
    473.81
    487.54
    537.82
    581.27
    623.41
    609.46
    596.69
    627.25
    640.87
    684.86
    354.41
    332.79
    - -
    748.25
    Book Value per Share
    419.01
    433.63
    501.83
    491.22
    514.09
    464.57
    466.65
    481.15
    477.02
    394.84
    455.57
    526.2
    621.97
    310.75
    299.43
    - -
    589.87
    Tangible Book Value per Share
    1,396
    1,363
    1,301
    1,228
    1,184
    1,176
    1,144
    1,137
    1,108
    1,096
    1,097
    1,086
    1,069
    2,081
    2,014
    973
    1,030
    Basic Weighted Avg Shares
    1,207,695
    1,197,313
    984,967
    951,359
    1,006,630
    1,149,427
    1,091,195
    1,114,784
    1,114,308
    1,100,039
    1,071,453
    1,149,370
    1,359,115
    1,439,231
    1,530,556
    - -
    751,227
    Sales/Revenue/Turnover
    5.74
    6.06
    7.23
    6.5
    7.4
    8.57
    7.43
    6.7
    4.86
    4.66
    9.32
    10.75
    10.64
    9.86
    7.03
    - -
    9.4
    Operating Margin (%)
    54,330
    48,220
    44,728
    47,335
    45,577
    50,852
    46,273
    51,783
    52,485
    61,986
    63,045
    66,234
    71,820
    78,298
    86,461
    - -
    40,596
    Depreciation Expense
    30,400
    41,754
    48,373
    42,159
    46,495
    71,292
    53,065
    60,124
    29,698
    18,837
    59,416
    75,725
    94,065
    87,121
    70,272
    - -
    40,664
    Net Income, GAAP
    25.95
    34
    45.36
    31.66
    29.95
    20.89
    25.05
    18.97
    32.35
    41.77
    32.59
    34.49
    28.47
    28.17
    25.44
    - -
    29.4
    Effective Tax Rate (%)
    2.52
    3.49
    4.91
    4.43
    4.62
    6.2
    4.86
    5.39
    2.67
    1.71
    5.55
    6.59
    6.92
    6.05
    4.59
    - -
    5.41
    Profit Margin (%)
    298,091
    302,920
    330,533
    312,680
    231,696
    374,129
    312,651
    324,049
    299,411
    203,335
    248,830
    256,788
    275,893
    208,063
    316,710
    - -
    -333,881
    Working Capital
    109,271
    104,837
    81,434
    104,428
    74,073
    243,226
    298,964
    309,711
    306,636
    273,685
    291,519
    271,281
    239,244
    254,224
    416,207
    - -
    442,401
    LT Debt
    650,291
    650,158
    691,710
    655,505
    725,331
    680,727
    690,673
    720,613
    685,960
    592,070
    667,846
    739,744
    822,968
    884,448
    813,273
    - -
    833,266
    Total Equity
    6.46
    6.08
    4.82
    5.17
    5.96
    8.18
    6.1
    5.76
    3.5
    3
    6.76
    7.74
    9.44
    8.28
    6.12
    - -
    3.82
    Return on Invested Capital (%)
    4.03
    5.48
    5.96
    4.75
    4.74
    7.25
    4.34
    5.29
    2.28
    1.25
    5.31
    7.18
    9.23
    6.98
    5.78
    - -
    2.76
    Return on Capital (%)
    6.28
    8.2
    8.9
    7.37
    8.02
    11.79
    8.18
    8.75
    4.29
    2.83
    8.85
    10.94
    13.17
    11.85
    9.98
    - -
    5.31
    Return on Common Equity (%)

    Capital Structure

    JPY

    •

    in mil. unless spec.
    Mar'24
    Jun'25
    Sep'25
    ST Debt
    188,270
    - -
    48,972
    LT Borrowings
    254,224
    - -
    442,401
    LT Finance Leases
    - -
    - -
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    1,025
    - -
    1,008
    Market Capitalization
    2,939,710
    2,930,556
    2,838,842

    Working Capital

    JPY

    •

    in mil. unless spec.
    Mar'24
    Jun'25
    Sep'25
    Total Current Assets
    - -
    - -
    - -
    Cash, Cash Equivalents & STI
    194,187
    - -
    196,124
    Accounts Receivable, Net
    185,564
    - -
    175,884
    Inventories
    287,122
    - -
    303,879
    Total Current Liabilities
    501,569
    - -
    333,881
    Payables & Accruals
    - -
    - -
    - -
    ST Debt
    188,270
    - -
    48,972
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    JPY

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    - -
    - -
    Free Cash Flow
    - -
    - -
    - -
    Net Income, GAAP
    - -
    - -
    - -
    Sales/Revenue/Turnover
    - -
    - -
    - -
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    JPY

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    339,521
    348,482
    379,641
    371,586
    1,439,231
    2025
    - -
    - -
    - -
    - -
    1,530,556
    2026
    - -
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    JPY

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    25.89
    18.5
    29.97
    - -
    41.86
    2025
    - -
    - -
    - -
    - -
    34.88
    2026
    - -
    - -
    - -
    - -
    - -

    Quarterly Dividends Per Share

    JPY

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    17.78
    0.46
    18.44
    - -
    18.45
    2025
    - -
    - -
    - -
    - -
    19.43
    2026
    - -
    - -
    - -
    - -
    - -
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • defenseworld.net

      Ajinomoto (OTCMKTS:AJINY) & Rocky Mountain Chocolate Factory (NASDAQ:RMCF) Critical Contrast

    • seekingalpha.com

      Ajinomoto Co., Inc. (AJNMY) Q1 2027 Earnings Call Transcript

    • wsj.com

      AI Needs Ajinomoto's Film, But Its CEO Won't Raise Prices Just Because

    • seekingalpha.com

      Ajinomoto Q4 Earnings: The Good And The Bad

    • defenseworld.net

      Analyzing J. M. Smucker (NYSE:SJM) and Ajinomoto (OTCMKTS:AJINY)

    • prnewswire.com

      Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing

    • wsj.com

      Is MSG Maker Ajinomoto Sitting on an AI Goldmine? This Investor Thinks So

    • defenseworld.net

      Critical Contrast: Ajinomoto (OTCMKTS:AJINY) vs. J. M. Smucker (NYSE:SJM)

    • businesswire.com

      Palliser Capital Publishes Value Enhancement Plan for Ajinomoto

    • seekingalpha.com

      Ajinomoto Co., Inc. (AJINY) Q3 2026 Earnings Call Transcript

    • seekingalpha.com

      Ajinomoto Co., Inc. (AJINY) Q2 2026 Earnings Call Transcript

    • seekingalpha.com

      Ajinomoto Co., Inc. - Special Call

    • seekingalpha.com

      Ajinomoto Co., Inc. (AJINY) Q1 2026 Earnings Call Transcript

    • seekingalpha.com

      Ajinomoto Co., Inc. (AJINY) Q4 2025 Earnings Call Transcript

    • globenewswire.com

      L-Phenylalanine Market Insights and Forecast to 2030 Featuring Profiles (SWOT, Sales, Prices) of Key Players - Evonik, Ajinomoto, Daesang, and Wuxi Jinghai Amino Acid Co.

    • globenewswire.com

      L-Alanyl-L-Glutamine Market Report 2025: Includes Insights Into the Sales, Revenue, Price, Gross Margin & SWOT of Kyowa Hakko, Ajinomoto, and Evonik

    • businesswire.com

      PCI Pharma Services to Acquire US-based Aseptic Fill-Finish CDMO Ajinomoto Althea

    • seekingalpha.com

      Ajinomoto Co., Inc. (AJINY) Q2 2024 Earnings Call Transcript

    • seekingalpha.com

      Ajinomoto Co., Inc. (AJINY) Q1 2024 Earnings Call Transcript

    • prnewswire.com

      Ajinomoto Co., Inc. Enhances StemFit iPS Cell Expansion Medium